Anti-CD3 antibodies for type 1 diabetes: beyond expectations

被引：40

作者：

Bach, Jean-Francois ^{[1
,2
]}

机构：

[1] Hop Necker Enfants Malad, INSERM, U1013, F-75015 Paris, France

[2] Univ Paris 05, Paris, France

来源：

LANCET | 2011年 / 378卷 / 9790期

关键词：

RECENT-ONSET; DOUBLE-BLIND; INSULIN; AUTOIMMUNITY; MELLITUS; TRIAL;

D O I：

10.1016/S0140-6736(11)60980-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：459 / 460

页数：2

共 12 条

[1] ANTI-CD3 ANTIBODY INDUCES LONG-TERM REMISSION OF OVERT AUTOIMMUNITY IN NONOBESE DIABETIC MICE [J].

CHATENOUD, L ;

THERVET, E ;

PRIMO, J ;

BACH, JF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (01) :123-127

[2] CD3-specific antibodies: a portal to the treatment of autoimmunity [J].

Chatenoud, Lucienne ;

Bluestone, Jeffrey A. .

NATURE REVIEWS IMMUNOLOGY, 2007, 7 (08) :622-632

[3]

FEUTREN G, 1986, LANCET, V2, P119

[4]

*GLAXOSMITHKLINE, 2011, GLAXOSMITHKLINE TOL

[5] Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus [J].

Herold, KC ;

Hagopian, W ;

Auger, JA ;

Poumian-Ruiz, E ;

Taylor, L ;

Donaldson, D ;

Gitelman, SE ;

Harlan, DM ;

Xu, DL ;

Zivin, RA ;

Bluestone, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (22) :1692-1698

[6] Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes [J].

Keymeulen, B ;

Vandemeulebroucke, E ;

Ziegler, AG ;

Mathieu, C ;

Kaufman, L ;

Hale, G ;

Gorus, F ;

Goldman, M ;

Walter, M ;

Candon, S ;

Schandene, L ;

Crenier, L ;

De Block, C ;

Seigneurin, JM ;

De Pauw, P ;

Pierard, D ;

Weets, I ;

Rebello, P ;

Bird, P ;

Berrie, E ;

Frewin, M ;

Waldmann, H ;

Bach, JF ;

Pipeleers, D ;

Chatenoud, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25) :2598-2608

[7] Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass [J].

Keymeulen, B. ;

Walter, M. ;

Mathieu, C. ;

Kaufman, L. ;

Gorus, F. ;

Hilbrands, R. ;

Vandemeulebroucke, E. ;

Van de Velde, U. ;

Crenier, L. ;

De Block, C. ;

Candon, S. ;

Waldmann, H. ;

Ziegler, A. G. ;

Chatenoud, L. ;

Pipeleers, D. .

DIABETOLOGIA, 2010, 53 (04) :614-623

[8] GAD treatment and insulin secretion in recent-onset type 1 diabetes [J].

Ludvigsson, Johnny ;

Faresjo, Maria ;

Hjorth, Maria ;

Axelsson, Stina ;

Cheramy, Mikael ;

Pihl, Mikael ;

Vaarala, Outi ;

Forsander, Gun ;

Ivarsson, Sten ;

Johansson, Calle ;

Lindh, Agne ;

Nilsson, Nils-Osten ;

Aman, Jan ;

Ortqvist, Eva ;

Zerhouni, Peter ;

Casas, Rosaura .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (18) :1909-1920

[9] β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277):: a randomised, double-blind, phase II trial [J].

Raz, I ;

Elias, D ;

Avron, A ;

Tamir, M ;

Metzger, M ;

Cohen, IR .

LANCET, 2001, 358 (9295) :1749-1753

[10] Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial [J].

Sherry, Nicole ;

Hagopian, William ;

Ludvigsson, Johnny ;

Jain, Sunil M. ;

Wahlen, Jack ;

Ferry, Robert J., Jr. ;

Bode, Bruce ;

Aronoff, Stephen ;

Holland, Christopher ;

Carlin, David ;

King, Karen L. ;

Wilder, Ronald L. ;

Pillemer, Stanley ;

Bonvini, Ezio ;

Johnson, Syd ;

Stein, Kathryn E. ;

Koenig, Scott ;

Herold, Kevan C. ;

Daifotis, Anastasia G. .

LANCET, 2011, 378 (9790) :487-497

← 1 2 →